Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma

NCT02148913 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Cohort 1: Carfilzomib 15 mg/m2
DRUG: Cohort 2: Carfilzomib 20 mg/m2
DRUG: Cohort 2b: Carfilzomib 20 mg/m2
DRUG: Cohort 3b: Carfilzomib 27 mg/m2

Sponsor

Corewell Health West